Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Strategy

Set Alert for Strategy

Takeda Introduces Vedolizumab In India Amid Signs Of Gear Shift

Takeda launches blockbuster gastrointestinal drug vedolizumab in India, stepping up the tempo on the back of the local base provided by its acquisition of Shire. More expansion in the country appears to be in store for the Japanese firm.

Commercial Strategy

Triple Joy For European Biotechs As FDA OKs Byfavo

Having secured FDA approval, the UK's Acacia Pharma will market Byfavo, the first new product in the sedation space in decades, which was licensed from Italy's Cosmo and developed by Germany's Paion.

Approvals Strategy

India Steps Up Scrutiny After Chinese API Prices, Military Tensions Rise

A recent military skirmish with China and a 35-40% average increase in prices of drug raw materials has seen India step up scrutiny of imports from the country. While the industry is seeking a hike in domestic formulations prices, product shortages are not expected in the short term.

Commercial Manufacturing

G1 Believes Boehringer Is Better Bet To Sell Trilaciclib

G1 Therapeutics had been talking about marketing its recently filed myelosuppression therapy for small cell lung cancer on its own. However a deal with Boehringer represents an alternative "capital efficient launch structure."

Cancer Deals

Ireland's Amryt Aiming For Success Stateside

With two revenue-generating products already on the market and Phase III data pending on Filsuvez for epidermolysis bullosa, CEO Joe Wiley has told Scrip that a US listing will give Amryt more visibility and credibility when it comes to future licensing and acquisition possibilities.

Strategy Rare Diseases

COVID-19 Unveils Social Media Might: Is Pharma Listening Hard Enough?

COVID-19 has generated a mind-boggling one billion-plus mentions on social media, unleashing unstructured big data rich in insights. Experts explain why pharma may well want  to“listen in” more raptly to such conversations across therapy areas while shaping some aspects of business strategy.

Commercial Strategy

Carlyle's 20% Stake Gives Piramal Pharma 'War Chest' For Growth

Private equity group Carlyle has acquired 20% of Piramal’s pharma business for close to $500m, with the Indian group expected to use the capital raise to bolster organic and inorganic growth and deleverage the balance sheet.

Commercial Deals

Stockwatch: MonarchE And Tug-Of-War Drug Development

With Lilly, Pfizer and Novartis duking it out for early-stage breast cancer patients, how many drugs for the same indication is too many?

Stockwatch Research and Development Strategies

Epidarex Closes £102m Fund To Back Budding UK Biotechs

The UK government is putting £50m into a fund that is aiming to build new life science companies based on world-class research and innovation from emerging hubs across the country.

StartUps and SMEs Financing
See All
UsernamePublicRestriction

Register